These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 7650289

  • 1. Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.
    Chirigos MA, Talor E, Sidwell RW, Burger RA, Warren RP.
    Immunopharmacol Immunotoxicol; 1995 May; 17(2):247-64. PubMed ID: 7650289
    [Abstract] [Full Text] [Related]

  • 2. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. Implications for the age-related decline in CTL.
    Bloom ET, Horvath JA.
    J Immunol; 1994 May 01; 152(9):4242-54. PubMed ID: 7908914
    [Abstract] [Full Text] [Related]

  • 3. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 5. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA.
    J Immunol; 1988 May 15; 140(10):3679-85. PubMed ID: 2896213
    [Abstract] [Full Text] [Related]

  • 6. A short synthetic peptide fragment of human interleukin-1 beta increases both human and murine natural killer activity.
    Peppoloni S, Bossù P, Boraschi D, Tagliabue A.
    Nat Immun Cell Growth Regul; 1989 May 15; 8(1):10-9. PubMed ID: 2785640
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of cytotoxic T lymphocyte and natural killer cell-mediated lysis by O,S,S,-trimethyl phosphorodithioate is at an early postrecognition step.
    Rodgers KE, Grayson MH, Ware CF.
    J Immunol; 1988 Jan 15; 140(2):564-70. PubMed ID: 3257244
    [Abstract] [Full Text] [Related]

  • 8. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.
    Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, Perussia B, Wolf SF, Starr SE, Trinchieri G.
    Eur J Immunol; 1993 Aug 15; 23(8):1826-30. PubMed ID: 8102101
    [Abstract] [Full Text] [Related]

  • 9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.
    Cancer Res; 2000 Sep 01; 60(17):4838-44. PubMed ID: 10987295
    [Abstract] [Full Text] [Related]

  • 10. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS.
    Exp Hematol; 2009 Oct 01; 37(10):1216-29. PubMed ID: 19638292
    [Abstract] [Full Text] [Related]

  • 11. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
    Tímár J, Forster-Horváth C, Lukits J, Döme B, Ladányi A, Remenár E, Kásler M, Bencsik M, Répássy G, Szabó G, Velich N, Suba Z, Elõ J, Balatoni Z, Bajtai A, Chretien P, Talor E.
    Laryngoscope; 2003 Dec 01; 113(12):2206-17. PubMed ID: 14660929
    [Abstract] [Full Text] [Related]

  • 12. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 Dec 01; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 13. IL-10: a novel cytotoxic T cell differentiation factor.
    Chen WF, Zlotnik A.
    J Immunol; 1991 Jul 15; 147(2):528-34. PubMed ID: 1906502
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effects of IL-2, IL-12 and IL-18 on cytolytic activity, perforin expression and IFN-gamma production of porcine natural killer cells.
    Pintaric M, Gerner W, Saalmüller A.
    Vet Immunol Immunopathol; 2008 Jan 15; 121(1-2):68-82. PubMed ID: 17913242
    [Abstract] [Full Text] [Related]

  • 15. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H, Lin KM, Chu TM.
    Cancer Res; 1990 Feb 15; 50(4):1107-12. PubMed ID: 2297759
    [Abstract] [Full Text] [Related]

  • 16. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
    Hirschowitz EA, Naama HA, Evoy D, Lieberman MD, Daly J, Crystal RG.
    Cancer Gene Ther; 1999 Feb 15; 6(6):491-8. PubMed ID: 10608345
    [Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.
    Thurman GB, Maluish AE, Rossio JL, Schlick E, Onozaki K, Talmadge JE, Procopio AD, Ortaldo JR, Ruscetti FW, Stevenson HC.
    J Biol Response Mod; 1986 Feb 15; 5(1):85-107. PubMed ID: 3514800
    [Abstract] [Full Text] [Related]

  • 18. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.
    Hefeneider SH, Conlon PJ, Henney CS, Gillis S.
    J Immunol; 1983 Jan 15; 130(1):222-7. PubMed ID: 6600178
    [Abstract] [Full Text] [Related]

  • 19. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B, Rees RC.
    Clin Exp Immunol; 1988 Nov 15; 74(2):162-5. PubMed ID: 3265652
    [Abstract] [Full Text] [Related]

  • 20. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB, Gutterman JU, Grimm EA.
    Cancer Res; 1988 Feb 15; 48(4):788-92. PubMed ID: 3257408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.